Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × selinexor × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4 Thoracic 3 Genitourinary 3 Plasma cell 2 Other hematologic neoplasm 2 Dermatologic 2 CNS 2 Tumor-Agnostic 1 Lymphoid 1

Conditions

Carcinoma, Squamous Cell 1 Carcinoma 1

Interventions

Gemcitabine 13 pembrolizumab 10 Capecitabine 9 Irinotecan 8 Erlotinib Hydrochloride 8 Carboplatin 8 Blood Specimen Collection 7 Paclitaxel 6 Nivolumab 6 Everolimus 6 Docetaxel 6 Cisplatin 6 Cetuximab 6 130-nm albumin-bound paclitaxel 6 vadimezan 5 Fluorouracil 5 Cyclophosphamide 5 trametinib 4 Leucovorin 4 Lapatinib 4 Bevacizumab 4 Albumin-Bound Paclitaxel 4 temsirolimus 3 atezolizumab 3 abemaciclib 3 Trastuzumab 3 Radiation 3 Pemetrexed 3 Methods 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02213133 2023-01-26

STARRS

Karyopharm Therapeutics Inc

Phase 2 Terminated

45 enrolled 12 charts

Carcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡